Long‐Term Outcome of Low‐ and High‐Dose Radioiodine for Thyroid Remnant Ablation
Authors' conclusion
The long-term effectiveness and safety of low-dose (1850 MBq) radioiodine are the same as those of high-dose (3700 MBq) radioiodine for thyroid remnant ablation in Chinese patients with low-risk DTC.
Study context
- Population
- Adults with low-risk differentiated thyroid cancer (DTC) in China after total or near-total thyroidectomy (± cervical lymph node dissection), T1-T3, ± lymph node metastasis, no distant metastasis; enrolled 2013–2014; mean age 42 years, 70.6% womenanalysed
- Participants
- 228 adults
- Comparison
- Low-dose vs high-dose radioiodine for remnant ablation
- Low-dosen = 117
- High-dosen = 111reference
- Primary endpoint
- Recurrence, survival and biochemical abnormalities
- Follow-up
- 3-5 and 6-10 years
Methodological detailsprospective, long-term follow-up
- Prospective
- Long-term follow-up
Primary result
As reported in the abstract
6-10-year follow-up
- Low-dose vs High-dose: all p > .05
Further findings
Recurrence
Survival rate
Original publication
Long‐Term Outcome of Low‐ and High‐Dose Radioiodine for Thyroid Remnant Ablation. Clin Endocrinol (Oxf). Published 4 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →